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Acute myeloid leukemia (AML) is a cancer of immature white blood cells of the myeloid line, which 
accumulate in the bone marrow and interfere with normal blood cell development. Chemotherapy is 
given over several induction phases to reduce or eliminate the cancer cells, called blasts. When the 
frequency of bone marrow blasts has been reduced to less than 5%, the disease is considered to be 
in complete remission. Although remission rates are quite high for young adults (up to 80%), only 30-
40% of patients survive more than five years following diagnosis. Many patients succumb to disease 
relapse due to the presence of a small number of blasts that remain following chemotherapy and 
continue to grow. Current monitoring methods use microscopic analysis of blast size, shape and 
granularity, but may miss rare cells or those without grossly different morphology. 
The presence of low-frequency cancer cells following chemotherapy, termed minimal residual 
disease (MRD), has been associated with an increased risk of relapse and poorer prognosis. Recent 
studies have focused on new and more sensitive methods to detect MRD, including the use of flow 
cytometry, which is a quantitative technique capable of rapidly detecting several surface and 
intracellular protein biomarkers that are present on millions of individual cells. The Clinical Research 
Division’s Dr. Soheil Meshinchi and colleagues now report on the use of a flow cytometry-based 
panel of 15 biomarkers to detect MRD in 340 children and young adults with AML. Use of this 
multidimensional flow cytometry panel to detect aberrant expression of surface biomarkers on AML 
blasts allowed the authors to identify residual disease in more patients than was detected using 
standard morphological characterization. Furthermore, the presence of MRD in patients strongly 
correlated with disease outcome and provided prognostic significance. 
Following induction chemotherapy, MRD was detected using standard morphological analysis and 
the cytometry biomarker panel. By morphology, 86% of patients were in complete remission (i.e. less 
than 5% blasts) after the first round of chemotherapy, which increased to 95% after a second round. 
The remaining patients had refractory or progressive disease, or were un-evaluable. The cytometry-
based panel detected MRD in 31% of all patients, with blast levels ranging from 0.02% to 85% of 
bone marrow (median 2%). Of the 86% of patients considered in complete remission following the 
first round of chemotherapy, 25% had detectable blasts using the cytometry panel. 
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Dr. Meshinchi et al. then examined relapse and survival outcomes associated with MRD to 
determine the clinical implications of this new, more sensitive detection method. The risk of relapse 
among patients who were morphologically in complete remission but had detectable MRD by 
cytometry was 60%, more than twice that of patients with no detectable residual disease. Similar 
results were seen following a second round of chemotherapy, and for disease-free and overall 
survival. Among patients with more than 5% blasts by morphological assessment, 74% were MRD 
positive and had a three-year survival rate of 35%. The remaining patients for whom the cytometry 
panel did not detect residual disease were all long-term survivors, suggesting that the cytometry 
panel also identifies patients with good prognosis., Genetic and molecular factors, such as the 
mutational status of specific genes or chromosome losses, can also categorize AML patients into 
distinct subgroups with unique relapse risks. However, a large number of patients lack any type of 
prognostic factors, for which this cytometry panel may be particularly useful. For all subgroups, 
including those deemed to have favorable, standard or high-risk disease features, presence of 
residual disease was highly correlated with poorer outcomes. 
The use of this cytometry biomarker panel will improve detection of residual disease and the 
allocation of additional therapies to patients. Patients with residual disease are likely to benefit from 
alternate therapies that are more intense, targeted or different formulations, whereas patients with 
undetectable disease may endure fewer or less intense treatments. 
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The use of flow cytometry to detect 
residual disease following 
chemotherapy improved the 
identification of patients with poor 
prognostic outcomes. A) Previously, 
morphological assessment of bone 
marrow was used to detect residual 
blasts based on shape and staining 
characteristics. B) New 
multidimensional flow cytometry 
uses a panel of 15 markers to label 
surface proteins on AML blasts and 
normal bone marrow cells. Based on 
these markers, cell size and 
granularlity, residual AML blasts are 
better detected an indicate patients 
who may need additional treatment. 
